Follow
@illumina 's acquisition of @GrailBio would have led to less innovation, less choice and higher prices for 🇪🇺 citizens & healthcare systems.
Preserving competition between early cancer detection test developers is vital. So today we prohibited the deal https://europa.eu/!b6RwHb
